Key result
Statin therapy during intensive care unit stay was not associated with a significant reduction in the incidence of venous thromboembolism compared to no statin therapy.
Why the study?
Does statin therapy reduce the incidence of venous thromboembolism in critically ill patients admitted to the ICU?
Cohort (n=798)
No
Does statin therapy reduce the incidence of venous thromboembolism in critically ill patients admitted to the ICU?
In critically ill patients, continuation or initiation of statin therapy during ICU stay was not associated with a significant reduction in VTE risk or hospital mortality.
Answers are grounded in this paper and cite their sources.
Statin use should not yet alter VTE prophylaxis in the ICU; leaves open a possible benefit requiring randomized confirmation.
BACKGROUND: Studies have shown that statins have pleiotropic effects on inflammation and coagulation; which may affect the risk of developing venous thromboembolism (VTE). The objective of this study was to evaluate the association between statin therapy during intensive care unit (ICU) stay and the incidence of VTE in critically ill patients. METHODS: This was a post-hoc analysis of a prospective observational cohort study of patients admitted to the intensive care unit between July 2006 and January 2008 at a tertiary care medical center. The primary endpoint was the incidence of VTE during ICU stay up to 30 days. Secondary endpoint was overall 30-day hospital mortality. Propensity score was used to adjust for clinically and statistically relevant variables. RESULTS: Of the 798 patients included in the original study, 123 patients (15.4%) received statins during their ICU stay. Survival analysis for VTE risk showed that statin therapy was not associated with a reduction of VTE incidence (crude hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.28-1.54, P=0.33 and adjusted HR 0.63, 95% CI 0.25-1.57, P=0.33). Furthermore, survival analysis for hospital mortality showed that statin therapy was not associated with a reduction in hospital mortality (crude HR 1.26, 95% CI 0.95-1.68, P=0.10 and adjusted HR 0.98, 95% CI 0.72-1.36, P=0.94). CONCLUSION: Our study showed no statistically significant association between statin therapy and VTE risk in critically ill patients. This question needs to be further studied in randomized control trials.
No takes yet. Share an insight, caveat, or question.
Harbi et al. (2013) conducted a cohort in Critical illness (n=798). Statin therapy vs. No statin therapy was evaluated on Incidence of venous thromboembolism during ICU stay up to 30 days (HR 0.63, 95% CI 0.25-1.57, p=0.33). Statin therapy during intensive care unit stay was not associated with a significant reduction in the incidence of venous thromboembolism compared to no statin therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: